Oncologic Drugs Advisory Committee

On Thursday, May 25, 2017, the Oncologic Drugs Advisory Committee (ODAC) supported, by a nearly unanimous vote of 14-Yes to 1-No, with no abstentions, the licensure of “Epoetin Hospira” as a biosimilar product to US-licensed Epogen/Procrit.